CN Mobile Logo


All Content

The combination of the attenuated oncolytic virus talimogene laherparepvec (T-VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well-tolerated by advanced melanoma patients.

Chemotherapy plus lenalidomide was shown to be inferior to high-dose melphalan and ASCT in transplant-eligible patients with newly diagnosed multiple myeloma.

Adding elotuzumab to lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma appears to result in better efficacy and safety.

A 68-year-old man presents with a cough and chest pain. Chest imaging shows a lung mass in the right upper lobe. What is your diagnosis?

The ALK inhibitor alectinib was highly active and well-tolerated in patients with ALK-rearranged, crizotinib-refractory, advanced non–small-cell lung cancer.

Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when adding nintedanib to carboplatin/paclitaxel.

In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.

The FDA has approved necitumumab (Portrazza) in combination with chemotherapy for the treatment of patients with metastatic squamous non-small-cell lung cancer.

A program implemented in New York City successfully increased colorectal cancer screening rates and diminished racial and ethnic disparities in screening.

Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.


By clicking Accept, you agree to become a member of the UBM Medica Community.